XML 22 R12.htm IDEA: XBRL DOCUMENT v3.25.2
INTANGIBLE ASSETS
 3 Months Ended
Jun. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

NOTE 6 - INTANGIBLE ASSETS

 

The Company acquired in process research and development costs and assembled workforce costs in connection with the Merger of Phytanix Bio.

 

As of June 30, 2025 and March 31, 2025, the Company has the following intangible assets:

 SCHEDULE OF INTANGIBLE ASSETS

   June 30, 2025   March 31, 2025 
In process research and development  $2,054,960   $- 
Assembled workforce   38,268    - 
Accumulated amortization   -    - 
Intangible assets, net  $2,093,228   $- 

 

The intangible assets identified will commence amortization upon a Phase 3 clinical trial for the drugs acquired. As of June 30, 2025, none of the trials have entered Phase 3. The Company will include these assets in their annual impairment test.